ReviewDigestive diseases and sciences2011
Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.
Review in Digestive diseases and sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 64 citations in OpenAlex.
- Effects of the vibrating capsule on colonic circadian rhythm and bowel symptoms in chronic idiopathic constipation.Neurogastroenterology and motility · 2020Trial
- Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial.World journal of gastroenterology · 2014Trial
- Comprehensive self-management reduces the negative impact of irritable bowel syndrome symptoms on sexual functioning.Digestive diseases and sciences · 2012Trial
- Reflections on 30 Years of Taking Care of Patients with Pelvic Floor Disorders.Clinics in colon and rectal surgery · 2025Review
- The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn's Disease but Not Ulcerative Colitis Patients.Pharmaceutics · 2023Article
- Chronic Constipation.Mayo Clinic proceedings · 2019Review
- Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation.Therapeutic advances in gastroenterology · 2018Review
- Opioid-Related Constipation in Patients With Non-cancer Pain Syndromes: a Review of Evidence-Based Therapies and Justification for a Change in Nomenclature.Current gastroenterology reports · 2017Review
- Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments.Frontiers in pharmacology · 2016Review
- New Options in Constipation Management.Current oncology reports · 2015Review
- Resting anal pressure, not outlet obstruction or transit, predicts healthcare utilization in chronic constipation: a retrospective cohort analysis.Neurogastroenterology and motility · 2015Article
- A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa.Pharmacology research & perspectives · 2015Article
- Effects of lubiprostone on pacemaker activity of interstitial cells of cajal from the mouse colon.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2014Article
- Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.World journal of gastroenterology · 2014Review
- Elobixibat and its potential role in chronic idiopathic constipation.Therapeutic advances in gastroenterology · 2014Review
- Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments.World journal of gastroenterology · 2014Review
- Drug development for the irritable bowel syndrome: current challenges and future perspectives.Frontiers in pharmacology · 2013Article
- American Gastroenterological Association technical review on constipation.Gastroenterology · 2013Review
- Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors.BMC pharmacology · 2012Article
- Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits?Naunyn-Schmiedeberg's archives of pharmacology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic constipation and IBS-C are two of the most common functional bowel disorders encountered by primary care providers and gastroenterologists, affecting up to 27% of the population in Western countries [1-4]. The treatment of these disorders is often empiric and most current therapies are indicated for episodic constipation. Over time, most patients become refractory to one or more laxatives. Lubiprostone (Amitiza) has been approved by the US Food and Drug Administration (FDA) for the treatment of chronic-idiopathic constipation [6]. It is an oral bicyclic fatty acid that selectively activates type 2 chloride channels in the apical membrane of the intestinal epithelial cells, hence stimulating chloride secretion, along with passive secretion of sodium and water, inducing peristalsis and laxation, without stimulating gastrointestinal smooth muscle. Several trials have shown it to be effective in the treatment of chronic idiopathic constipation, and recently also IBS-C. It has little systemic absorption and almost free of any serious adverse effects, however, occasionally can cause nausea. Based on the available evidence, it is reasonable to conclude that lubiprostone should be added to the short list of evidence-based pharmacotherapies for chronic constipation and IBS-C. Given the overlap between chronic constipation and IBS-C, clinicians can consider two strategies when deciding on the initial dose of lubiprostone. Based on current product labeling, it is recommended that 8 μg bid be started in patients with IBS-C whereas 24 μg bid be used in those with chronic constipation. Thus far, lubiprostone offers a novel approach to our therapeutic armamentarium, however, there is a need for more drugs with different mechanisms of action, in order to treat constipation that is often multifunctional.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.